Cite
Obando CA, Desanvicente-Celis Z, Gonzalez L, et al. Cost-Effectiveness Analysis of Abiraterone Acetate Treatment Compared with Cabacitaxel in the Republic of Panama, in Patients with Metastatic Castration-Resistant Prostate Cancer that Have Failed to Chemotherapy with Docetaxel. Value Health. 2014;17(7):A632doi: 10.1016/j.jval.2014.08.2261.
Obando, C. A., Desanvicente-Celis, Z., Gonzalez, L., Muschett, D., Gonzalez, F., & Goldberg, P. (2014). Cost-Effectiveness Analysis of Abiraterone Acetate Treatment Compared with Cabacitaxel in the Republic of Panama, in Patients with Metastatic Castration-Resistant Prostate Cancer that Have Failed to Chemotherapy with Docetaxel. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, 17(7), A632. https://doi.org/10.1016/j.jval.2014.08.2261
Obando, C A, et al. "Cost-Effectiveness Analysis of Abiraterone Acetate Treatment Compared with Cabacitaxel in the Republic of Panama, in Patients with Metastatic Castration-Resistant Prostate Cancer that Have Failed to Chemotherapy with Docetaxel." Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research vol. 17,7 (2014): A632. doi: https://doi.org/10.1016/j.jval.2014.08.2261
Obando CA, Desanvicente-Celis Z, Gonzalez L, Muschett D, Gonzalez F, Goldberg P. Cost-Effectiveness Analysis of Abiraterone Acetate Treatment Compared with Cabacitaxel in the Republic of Panama, in Patients with Metastatic Castration-Resistant Prostate Cancer that Have Failed to Chemotherapy with Docetaxel. Value Health. 2014 Nov;17(7):A632. doi: 10.1016/j.jval.2014.08.2261. Epub 2014 Oct 26. PMID: 27202248.
Copy
Download .nbib